Tarlov Cyst Disease Foundation
Knoxville, Tennessee
CHealth Score
43C
Financial Health Score
8-metric score across financial health, operational efficiency, and resilience. Based on IRS Form 990 filing data.
Below Average
💰
$21K
Total Revenue
📊
$37K
Total Expenses
🏦
$140K
Net Assets
📋
N/A
Total Liabilities
Financial Trends
5-Year Trend Analysis
Financial Health Indicators
Revenue Growth
-11.0%
Year-over-year change (2022 → 2023)
Net Margin
-76.1%
Revenue minus expenses as % of revenue
Filing History
13 filings on record| Year | Revenue | Expenses | Assets | |
|---|---|---|---|---|
| 2023 | $21,139↓11% | $37,221↓6% | $140,459↓10% | — |
| 2022 | $23,747↑16% | $39,760↑9% | $156,541↓9% | — |
| 2021 | $20,560↓44% | $36,540↑8% | $172,554↓8% | — |
| 2020 | $36,859↓13% | $33,888↑6% | $188,534↑2% | — |
| 2019 | $42,534↑24% | $31,875↑12% | $185,563↑6% | — |
| 2018 | $34,181↑29% | $28,546↓8% | $174,904↑3% | — |
| 2017 | $26,455↓51% | $31,190↑24% | $169,269↓3% | — |
| 2016 | $53,898↑30% | $25,222↓10% | $174,004↑20% | — |
| 2015 | $41,438↓17% | $27,892↑32% | $145,328↑10% | — |
| 2014 | $49,777↑7% | $21,196↑99% | $131,782↑28% | — |
| 2013 | $46,628↑153% | $10,678↑1040% | $103,201↑53% | — |
| 2012 | $18,415↓37% | $937↓99% | $67,251↑35% | — |
| 2011 | $29,236 | $76,515 | $49,773 | — |
Frequently Asked Questions
What does Tarlov Cyst Disease Foundation do?▼
Tarlov Cyst Disease Foundation is a medical research nonprofit organization based in Tennessee. It is classified under NTEE code H50 and is registered as a 501(c) tax-exempt organization with the IRS.
Is Tarlov Cyst Disease Foundation financially healthy?▼
Financial health scoring requires Form 990 filing data. Check back as we process more filings for Tarlov Cyst Disease Foundation.
How much revenue does Tarlov Cyst Disease Foundation generate?▼
Tarlov Cyst Disease Foundation reports $48K in annual revenue and holds $2.9M in total assets, based on IRS filings.
Similar Organizations
Explore more organizations in the Medical Research category, or browse all nonprofits in Tennessee.